Modulation of asparagine bioavailability and stress response signaling to enhance T cell robustness and maximize immunotherapy

T细胞的特异性、幅度和质量决定了肿瘤的发生、进展和对治疗的反应。两种最具革命性和前景的免疫疗法是免疫检查点阻断和过继细胞转移，它们都依赖于细胞毒性T效应细胞（Teff）的强大参与来控制或根除癌症。强大的T细胞介导的抗肿瘤反应需要营养和能量供应与Teff细胞扩增和功能的协调。然而，肿瘤细胞的高代谢需求通过竞争肿瘤微环境（TME）内的营养物而损害Teff细胞的功能。我们认为，限制患者对免疫治疗反应的关键屏障是肿瘤内的有害代谢微环境。我们先前已经证明，在T细胞活化和分化过程中，转录因子c-Myc和HIF 1 α是驱动中心碳代谢程序所需的差异。我们最近发现，天冬酰胺（Asn）是T细胞活化后上调最多的氨基酸，其生物利用度代表了Teff细胞中控制中心碳代谢和效应器功能的关键代谢节点。一些癌细胞仅依赖于细胞外Asn来支持生长和增殖，这代表了癌症的代谢脆弱性。然而，Teff细胞可以通过摄取细胞外Asn或从头合成Asn来维持细胞内Asn库以供细胞生长和功能，这表明T细胞具有一层代谢可塑性。细胞外Asn的强制限制重新连接中心碳分解代谢程序，导致Teff细胞中增强的抗肿瘤效应子功能。此外，这些Teff细胞的特征在于增强的ATF 4和Nrf 2信号传导应答。因此，我们假设Asn生物利用度的调节可以优化碳同化并整合应激反应信号通路，从而在代谢受限的肿瘤微阵列中实现稳健的抗肿瘤反应。为了验证我们的假设，我们建议：1）破译中心碳代谢途径的重编程，并评估关键代谢步骤对Teff细胞在Asn限制的背景下的影响; 2）确定ATF 4/Nrf 2轴在调节Teff细胞效应器功能中的作用; 3）靶向关键信号传导和代谢节点以工程化中心碳分解代谢程序，从而增强Teff细胞的功能和持久性，和4）开发和测试策略以同时利用Asn依赖性作为癌细胞代谢脆弱性并最大化全身抗肿瘤免疫。总的来说，该项目的完成将揭示肿瘤微环境，细胞代谢和抗肿瘤免疫之间新兴联系的基本原理。这些研究对于开发新方法，大幅改善癌症免疫治疗的临床结果至关重要。

Summary: The exquisite specificity, amplitude, and quality of T cells govern tumor initiation, progression, and responses to therapy. Two of the most revolutionary and promising immunotherapies are the immune checkpoint blockade and the adoptive cell transfer, which are both dependent on the robust engagement of cytotoxic T effector (Teff) cells to control or eradicate cancer. A robust T cell-mediated anti-tumor response requires the coordination of nutrient and energy supplies with Teff cell expansion and function. However, the high metabolic demands of tumor cells compromise the function of Teff cells by competing for nutrients within the tumor micro-environment (TME). We propose that the critical barrier, which limits the patient’s response to immunotherapy, is the hostile metabolic microenvironment within tumors. We have previously shown that the transcription factors c-Myc and HIF1alpha are differentially required for driving the central carbon metabolic programs during T cell acti-vation and differentiation. We recently revealed that asparagine (Asn) is the most upregulated amino acid upon T cell activation, and its bioavailability represents a key metabolic node that governs the central carbon metab-olism and effector function in Teff cells. Some cancer cells solely rely on extracellular Asn to support growth and proliferation, representing a metabolic vulnerability of cancer. However, Teff cells can maintain an intracellular Asn pool for cell growth and function either through the uptake of extracellular Asn or through de novo biosyn-thesis of Asn, indicating a layer of metabolic plasticity of T cells. Enforced restriction of extracellular Asn rewires central carbon catabolic programs, leading to enhanced anti-tumor effector function in Teff cells. Moreover, these Teff cells are characterized by an enhanced ATF4 and Nrf2 signaling response. Hence, we hypothesize that modulation of Asn bioavailability can optimize carbon assimilation and integrate stress-response sig-naling pathways, enabling a robust anti-tumor response in metabolically restricted tumor microenviron-ments. To test our hypothesis, we propose to 1) decipher the reprogramming of central carbon metabolic path-ways and assess the impact of key metabolic steps on Teff cells in the context of Asn restriction; 2) determine the role of ATF4/Nrf2 axis in regulating the effector function of Teff cells; 3) target critical signaling and metabolic nodes to engineer central carbon catabolic programs, thus enhancing function and persistence of Teff cells, and 4) develop and test strategies to simultaneously exploit Asn dependence as a cancer cell metabolic vulnerability and maximize systemic anti-tumor immunity. Collectively, the completion of this project will reveal fundamental principles of the emerging connections between the tumor’s microenvironment, cell metabolism, and anti-tumor immunity. These studies are critical to developing novel approaches that improve clinical outcomes of cancer immunotherapy substantially.